Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe

References

• Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol 2001;2:459-71
   PubMedGoogle Scholar
• Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010;21(Suppl 5):v93-7
   PubMed Web of Science ®Google Scholar
• Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000;343:905-14
   PubMed Web of Science ®Google Scholar
• Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000;355:1041-7
   PubMed Web of Science ®Google Scholar
• Goldberg R, Sargent D, Morton R, et al. A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar
• Douillard J, Siena S, Caissdy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as a first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
   PubMed Web of Science ®Google Scholar
• Peeters M, Price T, Hotko Y, et al. Randomised phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as a second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13
   PubMed Web of Science ®Google Scholar
• Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-24
   PubMedGoogle Scholar
• Tol K, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010;32:437-53
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluororopyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-7
   PubMed Web of Science ®Google Scholar
• Imclone Systems Inc. and Bristol-Myers Squibb Company. Erbitux® Summary of Product Characteristics, 2010
   Google Scholar
• Inoue Y, Toiyama Y, Tanaka K, et al. A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy. Jpn J Clin Oncol 2009;39:367-75
   PubMed Web of Science ®Google Scholar
• Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 2010;10(Suppl 1):S115-29
   PubMedGoogle Scholar
• Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, et al. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 2008;19:1600-4
   PubMed Web of Science ®Google Scholar
• Elferink MA, Krijnen P, Wouters MW, et al. Variation in treatment and outcome of patients with rectal cancer by region, hospital type and volume in the Netherlands. Eur J Surg Oncol 2010;36(Suppl 1):S74-82
   PubMedGoogle Scholar